Articles tagged with Drug Studies
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers have developed a groundbreaking method to observe lysosomes in live suspended cells—quantitatively, in 3D, and without the use of chemical labels. The technology uses holographic tomography in flow cytometry configuration (HTFC) to identify morphological and spatial lysosomal changes in models of lysosomal storage diseases.
Researchers Dr. Sharday Mosurinjohn and Dr. Richard Ascough critique the 'psychedelic mysteries hypothesis' in a new article, arguing that it relies on circumstantial evidence rather than solid historical scholarship. They advocate for responsible curiosity and a focus on living traditions to unlock psychedelic wisdom.
Researchers at Kyoto University have discovered a novel analgesic called ADRIANA, which targets the α2B-adrenoceptor and exerts its effect without causing cardiovascular instability. The compound has shown highly promising results in non-clinical studies and early clinical trials.
A new treatment for corneal scarring is being developed by University of Houston optometry researcher Tarsis G. Ferreira. The treatment uses a natural protein called decorin to block scarring and unwanted blood vessel growth, offering hope for people with injured corneas.
Researchers from FAU's Schmidt College of Medicine recommend using high-potency statins as the primary pharmacologic approach in treating and preventing cardiovascular disease. Lifestyle changes, such as regular physical activity and a healthy diet, are also crucial in reducing cardiovascular risk.
Researchers used an AI model to reassess a completed clinical trial for an Alzheimer's disease drug, finding it slowed cognitive decline by 46% in early-stage patients. The AI model predicts patient progression and allows for more precise selection of trial participants, potentially reducing the cost of developing new medicines.
Dr. Mirko Manchia's groundbreaking research identifies genetic markers predicting treatment response in bipolar patients, enabling precision medicine approaches to transform psychiatric care. He envisions a future where genetic testing becomes routine in psychiatric care.
Researchers have identified a hidden molecular mechanism involving two proteins that allows tumors to resist treatment. A new gelatin-based nanoparticle has been developed to shut down both proteins simultaneously, showing promising results in early studies with mice.
Clinical trials show sutezolid and delpazolid are safer alternatives to linezolid for treating drug-resistant TB, with no cases of nerve damage or blood toxicity reported. The findings suggest these drugs could replace linezolid in treatment regimens.
A new study highlights major hurdles for multinational clinical trials in Europe, including differences in timelines and processing times between countries. Researchers found that the UK made significant gains in efficiency during the pandemic, while non-UK countries lagged behind.
A team of researchers proposes a novel adaptive platform trial fund to accelerate ALS drug development. The study outlines a financing model that merges efficiencies with an innovative royalty-based investment structure, drawing on data from the HEALEY ALS Platform Trial. This new approach could transform how diseases like ALS are addr...
Researchers have discovered an oral drug called MA-5 that can improve both heart and muscle problems in patients with Barth syndrome, a rare genetic disorder. The drug boosts cellular energy production by up to 50% and protects cells from oxidative stress-induced death, addressing the underlying cause of the disease.
UVA Health received two anonymous $25 million estate gifts to support the Paul and Diane Manning Institute of Biotechnology. The institute will develop new treatments for hard-to-treat diseases with a state-of-the-art biomedical research facility expected to drive economic growth in Central Virginia.
A new study from Karolinska Institutet found that biological drugs used to treat severe asthma do not completely eradicate inflammatory cells. Researchers discovered an increase in blood levels of these cells during treatment, which could explain why inflammation often returns when treatment is tapered or discontinued. The study aims t...
A common medication used for autoimmune diseases has been found to be effective in treating giant cell arteritis, with nearly half of patients achieving sustained remission. The treatment reduces dependence on glucocorticoids, a common but side-effect-ridden option.
The experimental drug SANA has been shown to prevent fat accumulation, treat existing obesity, and reverse associated metabolic disorders. In animal tests, it activated thermogenesis through an unconventional mechanism, targeting adipose tissue cells to produce heat without involving the UCP1 protein.
Researchers at University of Cologne have discovered a previously unknown mechanism that explains why many patients with aggressive B-cell lymphoma don't respond to CAR-T cell therapy. Combining this innovative treatment with CSF1R inhibitors improves its effectiveness, according to the study published in Cancer Cell.
Researchers discover iguratimod, a rheumatoid arthritis drug, effectively treats excessive COVID-19 inflammation in mice by maintaining antiviral immune responses. The study provides hope for patients with severe COVID-19-related cytokine storms.
Researchers have discovered that nicotinamide riboside supplementation significantly improves NAD+ levels, reducing arterial stiffness, skin ulcer area, and kidney dysfunction. This breakthrough offers new hope for patients with Werner syndrome who lack effective treatment options.
Long-term data from the Phase 1/2 study of zigakibart demonstrate sustained proteinuria remission, stable kidney function, and a reassuring safety profile in patients with IgA nephropathy. The treatment also led to reductions in serum immunoglobulins, consistent with APRIL pathway inhibition.
The annual Alzheimer's disease drug development pipeline report, led by Dr. Jeffrey Cummings, highlights an increase in active clinical trials and promising drugs, offering reason for optimism. The report assesses 138 drugs currently being studied and notes the growing importance of biomarkers in clinical trials.
The S2302 Pragmatica-Lung trial found that the investigational combination of ramucirumab and pembrolizumab did not extend overall survival compared to standard-of-care treatments. The study enrolled a highly representative population of patients, establishing it as a paradigm-shifting model for large randomized studies.
A WVU microbiology student has discovered a new species of fungus, Periglandula clandestina, that produces effects similar to the semisynthetic drug LSD. The fungus is highly efficient at making ergot alkaloids, which can be used therapeutically to treat conditions like depression and addiction.
A Kennedy Krieger researcher's work on a promising oral drug, leriglitazone, has shown it can slow the progression of cerebral adrenoleukodystrophy (cALD) in all 11 trial participants. Nearly half of boys treated with the medication appeared to halt disease progression entirely.
DB-1310, a HER3-targeted antibody-drug conjugate, has shown real potential as a new treatment option for patients with advanced solid tumors that have progressed after standard therapies. In an international clinical trial, DB-1310 demonstrated significant tumor shrinkage and delayed cancer growth in 44% of EGFR-mutant NSCLC patients.
A new four-drug combination, DKRd, has emerged as a highly effective and safe treatment for newly diagnosed multiple myeloma patients. The ADVANCE clinical trial shows that 59% of patients treated with DKRd were MRD-negative after eight cycles of treatment, compared to 36% of KRd-treated patients.
The research aims to improve the survivability of wounded soldiers, enhance combat safety, and accelerate postoperative recovery in a multicenter pivotal clinical study. OYE's technology has shown promise in reducing mortality rates, lowering healthcare costs, and improving surgical workflow efficiency.
The ISSCR has assembled an international consortium to support the adoption of human stem cell-derived disease models for drug discovery and development. This initiative aims to reduce R&D costs and accelerate therapy development, aligning with efforts by regulatory bodies such as the FDA, NIH, and European Commission.
Researchers found that an inexpensive HIV drug can improve vision in patients with diabetic macular edema (DME) more effectively and at a lower cost than existing treatments. The drug, lamivudine, is taken orally and may represent a game-changing option for millions of patients worldwide.
A phase 3 trial announced today demonstrated lorundrostat's safety and effectiveness in reducing blood pressure in patients with resistant hypertension. The treatment, which blocks the production of aldosterone from the adrenal glands, achieved clinically meaningful and sustained reductions in systolic blood pressure.
The Center for Research Innovation in Biotechnology (CRIB) has developed a comprehensive database of active pharmaceutical ingredients with evidence of clinical testing. The database provides valuable information on drug discovery and development, including pricing, sponsors, and intended clinical applications.
Researchers found that denosumab increases tumour-infiltrating immune cells in early-stage breast cancer patients, particularly in type B luminal tumours. This increase is associated with a potential boost to the anti-tumor immune response and offers a valuable avenue for clinical interest.
A study reveals pharmacy care is perceived differently by diverse populations, with notable gaps in communication for patients with disabilities. The research highlights the importance of effective communication and accessible spaces for pharmacists to provide high-quality care.
A new head-to-head study has shown that tirzepatide results in around 50% more weight loss than semaglutide in adults with obesity. The study found that tirzepatide led to an average weight loss of 20.2%, significantly higher than the 13.7% achieved with semaglutide.
A real-world study of 1,752 patients with stage III or IV ovarian cancer found that adding bevacizumab to chemotherapy improved overall survival for those with advanced disease and residual cancer. Benefits were mostly seen in high-risk patients, not the general population.
A systematic review of available evidence found GLP-1 RAs lead to significant weight loss and improved blood sugar control in adults with severe mental illness. The analysis also showed that these medications were not associated with a worsening of mental state or suicidal behaviour.
Researchers found that patients taking HIV drugs called NRTIs are substantially less likely to develop Alzheimer's disease. The study, led by Jayakrishna Ambati, analyzed data from two large health insurance databases and determined a significant reduction in Alzheimer's risk among patients on NRTIs.
A clinical trial finds that moxidectin is more effective than current treatment ivermectin for lymphatic filariasis, a disease affecting millions in Africa. Moxidectin has a persistent effect and may require fewer rounds of treatment, potentially accelerating its elimination.
Rasika Dias, a renowned chemist at UTA, has been named a 2025 fellow of the Royal Society of Chemistry for his groundbreaking contributions to chemical sciences. He is the second chemistry faculty member to receive this honor.
A new gene therapy has successfully restored immune function in nine children with severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder. The treatment has eliminated symptoms and reduced severe infections, offering a life-changing benefit to these patients.
A Phase Ia/Ib trial found that zongertinib demonstrated clinical benefits for patients with advanced HER2-mutant non-small cell lung cancer, particularly those with specific HER2 mutations. The treatment showed a 71% objective response rate and manageable side effects.
A global research initiative analyzing data from nearly 2 million people in diverse populations worldwide has uncovered multiple new genes associated with osteoarthritis. The study also identified key genetic pathways and 69 genes whose protein products are targeted by approved drugs, paving the way for repurposed treatments.
The International Progressive MS Alliance has awarded €100,000 to three development project teams to plan clinical trials. The projects focus on developing new treatments for progressive MS, including exercise-induced fatigability, neural stem cell therapy, and salbutamol treatment.
A phase II trial found that pembrolizumab significantly reduced recurrence in patients with DNA mismatch repair-deficient early-stage solid cancers who had detectable circulating tumor DNA after surgery. The study suggests that using ctDNA to guide immunotherapy may help prevent relapse in high-risk patients.
A novel topical BRAF inhibitor gel called LUT014 has been shown to significantly reduce the severity of an acne-like rash in patients undergoing anti-EGFR therapies for colorectal cancer. The treatment's safety and effectiveness have been confirmed, offering a potential solution to managing this common side effect.
The treatment demonstrated early signals of efficacy, with 65.7% of patients experiencing lasting stable disease, and was generally well-tolerated, with most adverse events being mild and manageable.
A clinical trial found that LUT014, a topical BRAF inhibitor, significantly reduced the severity of acne-like skin rashes caused by targeted therapy for colorectal cancer. Patients who received LUT014 had improved quality of life and were able to continue receiving their cancer treatment with reduced side effects.
The study shows that Huo Xue Tong Luo capsule inhibits osteoclast formation and protects bone mass in ovariectomized mice. The PI3K-AKT signaling pathway is targeted to prevent bone loss induced by ovariectomy.
A study published in Food Chemistry: Molecular Sciences found that cinnamaldehyde in cinnamon activates receptors controlling medication clearance, raising concerns about potential interactions. Researchers recommend consulting a doctor before using cinnamon as a dietary supplement to avoid rapid clearance of prescription medicines.
Researchers identified a potential new treatment, lorundrostat, which reduced systolic blood pressure in individuals with uncontrolled or treatment-resistant hypertension. The study found a significant 15-point reduction in systolic blood pressure compared to placebo.
Researchers at Pennington Biomedical Research Center investigated tirzepatide's effects on weight loss and metabolic health. The study found that tirzepatide decreased calorie intake and increased fat oxidation, leading to significant weight loss. However, the drug did not decrease the slowing down of metabolic rate usually observed wi...
Researchers successfully treated atherosclerosis and fatty liver disease using DT-109 in nonhuman primates, which has potential as a dual therapy for two common conditions. The compound reduced the formation of atherosclerotic plaques and stopped critical processes that lead to vascular calcification.
This review compares the bioactive components and medicinal properties of natural and cultivated O. sinensis, highlighting differences in composition and effectiveness for specific therapeutic uses. Polysaccharides, nucleosides, sterols, and amino acids contribute to their health benefits, with natural specimens often exhibiting higher...
A new study reveals promising progress toward predicting how patients with major depressive disorder will respond to antidepressant medications. Brain connectivity patterns were found to significantly improve predictions of treatment response across two large, independent clinical trials.
Researchers developed an AI platform that tracks cancer biomarkers to personalize treatment dose adjustments for patients with advanced solid tumors. The study resulted in optimal doses being administered to 97.2% of patients, with average reductions of 20%.
A single dose of a psychedelic compound can enhance cognitive flexibility for weeks after administration, according to a groundbreaking study. Mice treated with the compound showed improved performance in reversal learning tasks compared to control groups when tested weeks later.
Researchers at Texas Tech University Health Sciences Center have received a $1.94 million grant to study inhibitors that target peripheral neuropathic pain. The project aims to develop novel non-opioid and non-addicting therapies capable of effectively managing chronic pain.
A new oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, Orforglipron, has demonstrated significant weight loss of 7.9% in individuals with diabetes and impaired glycemic control. The safety and tolerability of the medication are consistent with injectable therapies, making it a potentially accessible treatment option.
Adding an experimental cancer drug to standard TB treatment reduces lung damage and prevents post-TB lung disease in mice. Researchers found that the drug doubled pulmonary apoptosis and reduced lung scarring by 40% compared to standard treatments.
A new study found that both oral and injectable forms of naltrexone are effective in reducing heavy drinking among hospitalized patients. The medication was administered before discharge, resulting in a significant decrease in heavy drinking within the last 30 days of the three-month follow-up period.